SEC Form 4 · accession 0001159036-15-000057
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn E Falberg
Director
Period of report
May 6, 2015
Accepted (ET)
May 7, 2015 · 3:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 6, 2015 | A | 13,175 | $0.00 | A | 318,051 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents annual restricted stock grant under Directors Compensation Program as partial compensation for service on the Board. This grant will vest quarterly through the Company's next Annual Meeting Date.